Pfizer Inc. (NYSE:PFE) reported stronger‑than‑expected Q1 revenue but missed full‑year EPS guidance, sending the stock down about 8.5% to near $24.08, while the company faces a U.S. House probe into China trials and a judge ordered faster FDA release of COVID‑vaccine approval documents.
Previous Week Recap
- Pfizer Revenue Beat, Guidance Miss: Pfizer (PFE) Q1 revenue $14.45B, +5.4% YoY, beat estimates. Full-year EPS guidance missed consensus; stock down ~8.5% since earnings, trading near $24.08.
- Pfizer Probed In China Trials: Pfizer (PFE) said it received a letter from a U.S. House committee probing its China clinical trials. The company acknowledged the inquiry but gave no details on scope, timing or requests.
- FDA Ordered To Speed Vaccine Docs: Judge ordered FDA to speed release of documents used to approve Pfizer’s COVID-19 vaccine, citing delays; plaintiffs say FDA’s objections lacked reasonable basis — relevant for PFE traders.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.